| Not Yet Recruiting | A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer NCT07513311 | Massachusetts General Hospital | N/A |
| Not Yet Recruiting | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. NCT07509515 | Fudan University | Phase 2 |
| Not Yet Recruiting | Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (T NCT07527819 | Peter MacCallum Cancer Centre, Australia | — |
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer NCT06768931 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Tri NCT07276880 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease NCT07069595 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer NCT07342283 | Affiliated Hospital of Nantong University | Phase 2 |
| Active Not Recruiting | Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer NCT07484776 | Universidad Europea de Madrid | N/A |
| Recruiting | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) NCT07486089 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Adjuvant Intensification for LAR NCT07407517 | Fudan University | Phase 3 |
| Not Yet Recruiting | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tu NCT07272642 | Radiopharm Theranostics, Ltd | Phase 1 |
| Recruiting | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC NCT07208149 | Shenzhen Majory Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab NCT07187674 | Harbin Medical University | N/A |
| Enrolling By Invitation | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid T NCT07218003 | Rondo Therapeutics | Phase 1 |
| Not Yet Recruiting | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis NCT07246759 | OncoHost Ltd. | — |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Recruiting | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer NCT07190469 | ProteinQure Inc. | Phase 1 |
| Not Yet Recruiting | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer NCT07161791 | Harbin Medical University | Phase 1 / Phase 2 |
| Recruiting | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06732323 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative NCT07153965 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer ( NCT06975644 | Zhejiang Provincial People's Hospital | N/A |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors NCT07020117 | Aktis Oncology, Inc. | Phase 1 |
| Recruiting | Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast NCT06606730 | UNICANCER | Phase 3 |
| Not Yet Recruiting | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Ho NCT07005583 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Active Not Recruiting | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer NCT06878248 | Calibr, a division of Scripps Research | Phase 1 |
| Recruiting | OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal NCT06476119 | The Netherlands Cancer Institute | — |
| Not Yet Recruiting | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Th NCT06910072 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 / Phase 3 |
| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple NCT06767527 | Akeso | Phase 3 |
| Recruiting | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Nega NCT07394387 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | The Optimal Radioimmunotherapy Combinations for Advanced TNBC NCT06735131 | Sun Yat-sen University | Phase 2 |
| Recruiting | BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC NCT06793332 | Fudan University | Phase 2 |
| Active Not Recruiting | Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer NCT07046195 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Not Yet Recruiting | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in t NCT06724263 | Tasly Biopharmaceuticals Co., Ltd. | Phase 2 |
| Not Yet Recruiting | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC NCT06731153 | Fudan University | Phase 2 |
| Recruiting | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic T NCT06636981 | Fudan University | Phase 2 |
| Recruiting | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 | Fudan University | Phase 2 |
| Not Yet Recruiting | JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases NCT06586866 | JenKem Technology Co., Ltd. | Phase 2 |
| Recruiting | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha NCT06547840 | Epsilogen Ltd | Phase 1 |
| Recruiting | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy NCT06880029 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. | Phase 1 / Phase 2 |
| Recruiting | Study of XB010 in Subjects With Solid Tumors NCT06545331 | Exelixis | Phase 1 |
| Recruiting | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC NCT06419621 | Biotheus Inc. | Phase 3 |
| Active Not Recruiting | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2- NCT06782698 | Centro Hospitalar Universitário de Santo António | N/A |
| Recruiting | Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) NCT06189209 | Rhizen Pharmaceuticals SA | Phase 2 |
| Active Not Recruiting | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 | Arcus Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer NCT05949021 | Mridula George, MD | Phase 2 |
| Active Not Recruiting | A Study of ADRX-0706 in Select Advanced Solid Tumors NCT06036121 | Adcentrx Therapeutics | Phase 1 |
| Recruiting | a Single-arm, Single-center, Open Clinical Study NCT06431100 | Beijing Geekgene Technology Co., LTD | — |
| Recruiting | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj NCT05827614 | Boundless Bio, Inc. | Phase 1 |
| Recruiting | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, NCT05706129 | ITM Oncologics GmbH | Phase 1 / Phase 2 |
| Recruiting | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA I NCT07073755 | Hunan Cancer Hospital | — |
| Recruiting | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors NCT05490472 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer NCT05555706 | Shanghai Jiaolian Drug Research and Development Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 | Fudan University | Phase 2 |
| Active Not Recruiting | Onvansertib + Paclitaxel In TNBC NCT05383196 | Antonio Giordano, MD | Phase 1 / Phase 2 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Recruiting | A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 | Nurix Therapeutics, Inc. | Phase 1 |
| Unknown | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer NCT05088057 | Aiping Shi | Phase 2 |
| Terminated | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors NCT04424641 | Genmab | Phase 1 / Phase 2 |
| Recruiting | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study NCT03740893 | Institute of Cancer Research, United Kingdom | Phase 2 |
| Active Not Recruiting | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABB NCT03893955 | AbbVie | Phase 1 |
| Unknown | A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC NCT03855358 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Terminated | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cance NCT03742349 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | A Phase 1 Study of [225Ac]-FPI-1434 Injection NCT03746431 | Fusion Pharmaceuticals Inc. | Phase 1 |
| Withdrawn | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine NCT03554109 | ImmunityBio, Inc. | Phase 2 |
| Terminated | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Mal NCT03549000 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Loca NCT02819518 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-862 NCT02698176 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participan NCT02178722 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | AZD8186 First Time In Patient Ascending Dose Study NCT01884285 | AstraZeneca | Phase 1 |
| No Longer Available | Expanded Access to Veliparib NCT03123211 | AbbVie | — |